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SNAREs provide a large part of the specificity and
energy needed for membrane fusion and, to do so,
must be localized to their correct membranes.
Here, we show that the R-SNAREs VAMP8, VAMP3,
and VAMP2, which cycle between the plasma
membrane and endosomes, bind directly to the ubiq-
uitously expressed, PtdIns4,5P2-binding, endocytic
clathrin adaptor CALM/PICALM. X-ray crystallog-
raphy shows that the N-terminal halves of their
SNARE motifs bind the CALMANTH domain as helices
in a manner that mimics SNARE complex formation.
Mutation of residues in the CALM:SNARE interface
inhibits binding in vitro and prevents R-SNARE
endocytosis in vivo. Thus, CALM:R-SNARE interac-
tions ensure that R-SNAREs, required for the fusion
of endocytic clathrin-coated vesicles with endo-
somes and also for subsequent postendosomal
trafficking, are sorted into endocytic vesicles.
CALM’s role in directing the endocytosis of small
R-SNAREs may provide insight into the association
of CALM/PICALMmutations with growth retardation,
cognitive defects, and Alzheimer’s disease.
INTRODUCTION
SNAREs (Soluble NSF Attachment Protein REceptors) are small
membrane-anchored proteins that lie at the heart of the vesi-
cle:organelle and organelle:organelle membrane fusion
machinery, providingmuch of the energy and specificity required
for membrane fusion (Hong, 2005; Jahn and Scheller, 2006; Sut-
ton et al., 1998). Aswith all membrane proteins, SNAREsmust be
positioned in their appropriate cellular location in order to func-
tion correctly. In recent years, it has become apparent that the
cell possesses mechanisms for transporting SNAREs between
its various membranes alongside standard (non-SNARE) cargo.1118 Cell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc.Here, we investigate the molecular mechanism by which the
SNAREs VAMP8, VAMP3, and VAMP2 are internalized from
the plasma membrane.
There are at least 38 SNAREs in mammalian cells (Bock et al.,
2001; Hong, 2005; Kloepper et al., 2007). Most contain a single
conserved helical SNARE motif of 60–70 residues, although
SNAP23, SNAP25, and SNAP29 contain two (Jahn and Scheller,
2006). N-terminal to their SNARE motifs, most SNAREs have
a folded region that varies in length from 100–150 residues and
is usually either a three helical Habc domain or a longin domain
(reviewed in Hong, 2005). SNARE complexes are formed when
four SNARE motifs come together as a tetrameric coiled-coil
(Sutton et al., 1998). Three of these SNAREmotifs are associated
with one membrane and derive from the so-called Q-SNAREs,
while the other SNARE motif is provided by an R-SNARE that
resides in the membrane that will fuse with the first membrane
(Fasshauer et al., 1998). It is this relative orientation of the (Q-)
and (R-) SNAREs that draws the two membranes close enough
to drive their fusion. The specificity of vesicle:organelle and
organelle:organelle fusion arising from the limited combinations
of SNAREs that can form complexes can only come about if
the localization of SNAREs is itself controlled. For instance,
SNAREs must be transported to a given organelle membrane
so that they can subsequently be sorted into transport vesicles
and tubules leaving that membrane since this enables these
transport vesicles/tubules to fuse, ultimately, with their desired
target membrane, into which the correct cognate SNAREs
must have already been placed.
The active sorting of SNAREs into transport vesicles/tubules is
achieved primarily by direct interaction with components of the
vesicle/tubule’s protein coat, although transmembrane helix
length may also play a role (Sharpe et al., 2010). Initial mecha-
nistic descriptions of active SNARE sorting came from studies
on COPII coated vesicles, which mediate ER to Golgi transport
(Mancias and Goldberg, 2007; Mossessova et al., 2003). In
post-Golgi trafficking, the sorting of Vti1b by EpsinR (Miller
et al., 2007) and of VAMP7 by Hrb (Pryor et al., 2008) and AP3
(Martinez-Arca et al., 2003) are mediated by the direct interac-
tions of the folded N-terminal domains of the SNAREs with the
respective coated vesicle adaptors. Since the molecular mech-
anisms by which these latter recognition events occur are
distinct from those by which conventional short, linear motif
(YxxF, ExxxLL, FxNPxY) containing cargo are recognized (Boni-
facino and Traub, 2003), the two systems are noncompetitive
and so can act in parallel to ensure that both SNAREs and cargo
are incorporated into transport vesicles.
VAMP8 and VAMP3 cycle between the cell’s limiting
membrane and early endosomes/recycling endosomes and
thus mediate the fusion of vesicles with both compartments,
whereas VAMP2 drives the fusion of fast-recycling synaptic vesi-
cles with the plasmamembrane (Antonin et al., 2000; Grote et al.,
1995; McMahon et al., 1993). None of these three SNAREs have
a conventional cargo motif (such as the ExxxLL motif found on
VAMP4 [Peden et al., 2001]), nor do they possess folded
N-terminal domains. However, preceeding their SNARE motifs
there are short regions of 10–30 residues that are predicted to
be unstructured (Ellena et al., 2009; Fiebig et al., 1999; Hazzard
et al., 1999). The question thus arises: how are these SNAREs
sorted into endocytic clathrin-coated vesicles? Based on the
observations that both Vti1b and VAMP7 can be transported
as part of a cis-SNARE complex (Miller et al., 2007; Pryor
et al., 2008), one possibility was that VAMPs 8, 3, and 2 could
be internalized as a complex with their acceptor (Q-) SNAREs
(a syntaxin and a SNAP) (Gordon et al., 2009). However, endo-
cytic and synaptic vesicles contain a large excess of these small
R-SNAREs over their acceptor (Q-) SNAREs (Takamori et al.,
2006) and in addition, the steady state localization of VAMPs 8,
3, and 2 is endosomal, whereas that of syntaxins1-4 and SNAPs
is at the plasma membrane. Together, these observations
suggest that trafficking of small R-SNARE VAMPs as part of
a complex is unlikely.
In this study, we provide structural, biochemical and in vivo
data to show that the internalization of VAMP8, and conse-
quently that of the highly related small R-SNAREs, VAMP3 and
VAMP2, is mediated by specific, direct interactions between
the N-terminal halves of their SNARE motifs and the ANTH
(AP180 N-terminal Homology) domain of the endocytic clathrin
adaptor CALM.
RESULTS
CALM Is Involved in theEndocytosis of VAMPs2, 3, and8
Recent in vivo studies (Harel et al., 2008) suggested that the
ubiquitously expressed CALM and possibly its neuronal specific
homolog AP180 (Dreyling et al., 1996; Lindner and Ungewickell,
1992; Yao et al., 2003), may play a role in the trafficking of
VAMP2 in mammalian cells. This supported earlier work in
D. melanogaster (Bao et al., 2005), C. elegans (Nonet et al.,
1999), and yeast (Burston et al., 2009), suggesting that these
organisms’ single ANTH domain containing clathrin adaptor
proteins were involved in the endocytosis of short endocytic
R-SNARE VAMPs.
To confirm a role for CALM in the trafficking of VAMP2 and to
show that CALM was similarly involved in endocytosis of the
related small endocytic R-SNAREs VAMP3 and VAMP8 (Hong,
2005), we investigated the effect of CALM depletion on
VAMP2, VAMP3, and VAMP8 endocytosis. The three SNAREsCwere tagged with a double HA epitope at their (lumenal)
C-termini (termed VAMP2-HA, VAMP3-HA, and VAMP8-HA)
(Gordon et al., 2009) and were stably expressed in HeLa cells
at relatively low levels (Figure S1A available online). Depletion
of CALM by siRNA caused all three SNAREs to accumulate on
the cell surface (Figure 1A). To investigate the rate of endocytosis
of the three HA-tagged VAMPs, we used a flow cytometry-based
antibody uptake assay (as outlined in Figure S1B). In control
cells, the three SNAREs were rapidly internalized, with 40%–
60% of the prebound antibody already inside the cells after
5 min. However, when CALM was depleted, antibody uptake
was negligible even after 30 min (Figure 1). These effects are
considerably more dramatic than previously reported (Harel
et al., 2008), presumably because we expressed the constructs
at lower than endogenous levels so as not to saturate the intra-
cellular sorting machinery. The inhibition of VAMP endocytosis
was rescued by expression of Myc-tagged, full-length, siRNA-
resistant CALM, indicating that the phenotype is specific and not
an off-target effect (Figure 1B and Figure S1C). In agreement
with previous studies (Harel et al., 2008; Huang et al., 2004), the
endocytosis rates of standard cargoes such as EGF and TfR
were not significantly altered by CALM depletion (Figure S1D).
VAMPs 2, 3, and 8 Bind Directly to CALMANTH
To investigate the possibility of a direct interaction between any
of these small R-SNAREs and the ANTH domain of CALM
(defined as residues 19–289 [Ford et al., 2001]), we carried out
‘‘GST pull-down’’ binding assays using recombinantly
expressed proteins. As shown in Figure 2A the three SNAREs
interacted directly with the CALMANTH domain in a concentra-
tion-dependent manner. Isothermal titration calorimetry (ITC)
was used to quantify the strength of binding. The interaction
between GST-VAMP8 and CALMANTH is the tightest with a KD
of 18 mM (Figure 2B), which is typical for a dynamic cargo/
coat interaction (Owen et al., 2004; Pryor et al., 2008). Binding
of the CALMANTH domain to GST-VAMP3 and GST-VAMP2,
although similar to one another (46 mM and 43 mM respec-
tively), were weaker than the binding to VAMP8 (Figure 2B).
These differences in affinities are reflected in the relative rates
of endocytosis of the three VAMPs (Figure 1B). No interaction
could be detected between any of the three R-SNAREs and
the related ENTH domain of the endocytic clathrin adaptor,
epsin1.
The ANTH domains of CALM and neuronal specific AP180
share 82% sequence identity. However, in our hands, the
ANTH domain of mammalian AP180 showed no significantly
measurable binding to mammalian VAMPs 2, 3, or 8 by GST
pull-downs or surface plasmon resonance (SPR) (Figure S2A
and S2B), despite being correctly folded as indicated by circular
dichroism (CD) (data not shown) and being competent to bind
PtdIns(4,5)P2 similarly to CALMANTH by ITC (Figure S2C) and
liposome-based SPR (data not shown). We have no simple
explanation for this, but note that AP180 and CALM are not func-
tionally redundant (Bushlin et al., 2008; Harel et al., 2008) and
that the single ANTH domain containing clathrin adaptor in lower
organisms is more like CALM than AP180 (Harel et al., 2008).
Taken together with the in vivo studies published by others
and presented here, our biochemical data point to the directell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc. 1119
Figure 1. CALM Depletion Abolishes Endo-
cytosis of HA-Tagged VAMPs
(A) Effect of CALMdepletion on surface expression
of HA-tagged VAMPs. Control and siRNA-treated
cells expressing HA-tagged VAMP2, VAMP3, or
VAMP8 were mixed together, fixed without per-
meabilization, and labeled with anti-HA, then per-
meabilized and labeled with anti-CALM. Knocking
down CALM increases the surface expression of
all three VAMPs. The scale bar represents 20 mm.
(B) Endocytosis of anti-HA in cells expressing
HA-tagged VAMPs. Antibody was bound to the
cells at 4C, then the cells were warmed to 37C
for 2–30 min and antibody remaining at the cell
surface was quantified by flow cytometry. Each
point is derived from at least three separate
experiments; the error bars show the SEM.
Knocking down CALM effectively abolishes the
uptake of all three VAMPs. The specificity of
the knockdown phenotype was demonstrated
by stably transfecting VAMP8-HA-expressing
cells with siRNA-resistant myc-tagged CALM
(CALMres wt) and knocking down endogenous
CALM. Expression of the CALM construct almost
completely rescues the knockdown phenotype.
See also Figure S1.binding of the VAMPs 2, 3, and 8 by CALM being directly respon-
sible for the endocytosis of these small R-SNAREs. Hence, we
set out to investigate the molecular basis for this interaction
using a combination of structure determination and in vitro and
in vivo assays using wild-type and structure-directed mutant
versions of both proteins. Because their sequence similarities
(Figure 3A) and similar binding affinities indicated a conserved
mechanism of interaction for the three SNARES, for technical
reasons we characterized at the structural level only the interac-
tion between CALMANTH and the R-SNARE to which it bound
most tightly, VAMP8.
The N-Terminal Half of the VAMP8 SNARE Motif Binds
to CALMANTH
In order to delineatewhich portion of VAMP8binds toCALMANTH,
a number of deletion constructs were made (Figure 3B), an
approach we deemed acceptable since several studies (Fassha-
uer et al., 1997; Fiebig et al., 1999; Hazzard et al., 1999) have
shown small VAMPs to have no secondary structure in solution.1120 Cell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc.GST pull-down experiments using trun-
cated versions of VAMP8 (Figure 3C) re-
vealed that the minimal region necessary
for binding was residues 10-41 i.e., the
N-terminal half of the SNARE motif. ITC
showed that the binding of residues
10-41 of VAMP8 was almost identical
(KD 20 mM) to that of wild-type VAMP8
(KD 18 mM) (Figure 3D), indicating that
all the determinants for CALM binding
are contained within residues 10-41.
Significantly, the corresponding regions
of mammalian VAMP2 and of the yeastendocytic VAMP Snc1p contains two key residues, Val43 and
Met46 (VAMP2 numbering), which, when mutated to alanines,
blocks their endocytosis (Grote et al., 1995; Lewis et al., 2000).
In agreement with these data, we found that mutation of these
residues to alanines in VAMP2-HA and likewise of the analogous
residues in VAMP3-HA (Val30 andMet33) and VAMP8-HA (Lys24
and Met27) blocked their internalisation from the cell surface
(Figures 3E and S3).
The VAMP8 SNARE Motif Binds in Place
of the CALMANTH Final Helix
Attempts were made to crystallize a complex of CALMANTH with
a peptide corresponding to residues 10–41 of VAMP8, both with
the two components free in solution and with residues 10–41 of
VAMP8 appended on the C terminus of CALMANTH. While these
cocrystallizations did not yield the structure of a complex, they
did yield a 1.8A˚ resolution structure (final R/Rfree 0.182/0.216;
see Table S1) of the unliganded ANTH domain with two mole-
cules in the asymmetric unit. In both molecules the positions of
Figure 2. CALM Binds Directly to VAMP8, VAMP3, and VAMP2
(A) GST Pull downs using His6MycCALMANTH and theGST-fusion proteins indicated. Top: Coomassie blue stained gel. Lower: western blot probedwith anti-myc.
In this and all subsequent experiments, the lane adjacent to the Molecular weight markers (MWM) is loaded with His6MycCALMANTH only. The ANTH domain of
CALM binds directly to VAMP2, 3, and 8 in a concentration dependent manner.
(B) ITC quantitating the binding of CALMANTH to VAMP2, 3, and 8 (black squares). The Adaptor:SNARE interaction was tightest for VAMP8 (KD17 ± 1mM) and
weaker for both VAMP3 and VAMP2, (46 ± 7 mM and 48 ± 4 mM, respectively). EpsinENTH showed no VAMP binding (black triangles) indicating the CALM:SNARE
interaction is specific. Data for epsin1 is offset by 0.3 mcal/sec for clarity.
See also Figure S2.the first ten helices are identical. The C-terminal 25 residues of
the ANTH domain were poorly ordered in one molecule of the
asymmetric unit, as in the published CALMANTH structure deter-
mined from crystals of a different spacegroup (1HF8; Ford et al.,
2001), while in the other molecule the C terminus was con-
strained by crystal packing and formed a four-turn helix (Fig-
ures 4 and S4A). The CALMANTH structures presented here in
conjunction with the previously published structure (Ford et al.,
2001) suggested that residues 265–289 of CALM are not integral
to the ANTH domain but are flexible and associate only weakly
with the domain’s core residues (19–264). Inspection of the
CALMANTH surface showed that the elongated patch on which
the ordered short helix 11 and preceding ten residues of CALM
sat was hydrophobic in nature and of the correct dimensions
to bind an a helix and was thus a good candidate for the interac-
tion site for the hydrophobic SNAREmotif of a VAMP (Figure 4B).
If this hydrophobic trough were indeed the VAMP binding site on
CALMANTH, then deletion of helix 11 would be expected toCincrease VAMP8 binding. However, a truncated CALMANTH
construct missing helix 11 and the preceding ten residues,
termed CALMANTH(1-264), unexpectedly showed no binding to
VAMP8 by GST pull-down experiments and ITC (Figures 4C
and 4D) while still displaying normal binding to PtdIns4,5P2
containing liposomes by SPR (data not shown). Multiangle light
scattering (MALS) indicated that in solution CALMANTH(1-264) is
in fact a tight dimer (Figure S4B). This was confirmed by the
determination of the structure of CALMANTH(1-264) at 1.7A˚ resolu-
tion (final R/Rfree 0.170/0.191; see Table S1). The dimeric struc-
ture explained the lack of VAMP8 binding since the dimer inter-
face (burying 2100A˚2 of accessible surface area in total (Krissinel
and Henrick, 2007)) was the proposed VAMP8 binding site
(Figures 4E and 4F). As there were no other significant changes
between the surfaces of CALMANTH and CALMANTH(1-264), these
data strongly indicated that the hydrophobic trough in which
helix 11 (when formed) sits was indeed the VAMP8 binding site
on CALMANTH.ell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc. 1121
Figure 3. The N-Terminal Half of the Small
R-SNARE VAMPs Binds to CALMANTH
(A) Sequence alignment of the SNARE motifs of
VAMP2, VAMP3, Snc1p, and VAMP8. Conserved
residues are boxed in gray. The position of
mutated residues in VAMP8: L16 and V23 (open
triangles), K24 and M27 (black circles), L44 and
L51 (open circles) are indicated.
(B) Schematic representationof truncationmutants
of VAMP8.
(C) GST pull-down experiments using
His6MycCALMANTH and the GST-fusion proteins
indicated. Top panel: Coomassie blue stained gel.
Lower panel: western blot probed with anti-myc.
The minimal fragment of VAMP8 that is able to
bind to CALM with a similar affinity as the full
cytoplasmic portion of VAMP8 (residues 1–76)
comprises residues 10–41.
(D) ITC quantitating the binding of CALMANTH to
truncated VAMP8. VAMP810-41 (black triangles)
exhibited an essentially identical binding affinity
to CALMANTH as VAMP81-76 (black squares)
(KDs 17 ± 1 mM and 20 ± 3 mM respectively). Data
for VAMP8(10-41) is offset by 1.3 mcal/s for clarity.
(E) Localization of anti-HA in cells expressing
different wild-type or mutant HA-tagged VAMPs.
The cells were allowed to endocytose the antibody
for 40 min, then processed for immunofluores-
cence. The cells expressing wild-type VAMP2-HA,
VAMP3-HA and VAMP8-HA have endocytosed
the antibody, but the cells expressing the VAMP2-
HAV43AM46A, VAMP3-HAV30AMetA, and
VAMP8-HAK24AM27A mutants have retained the
antibody on the plasma membrane. The scale bar
represents 20 mm.
See also Figure S3.Structure of a CALMANTH(1-264): VAMP8(11-41)
Chimeric Complex
In an attempt to obtain a structure of a complex between
CALMANTH and VAMP8, a construct was designed in which resi-
dues 11–41 of VAMP8were fused through an artificial linker of six1122 Cell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc.residues to residues 1–264 of CALMANTH.
The resulting chimeric protein
(CALMANTH(1-264):VAMP8(11-41)) crystal-
lized and its 2.0 A˚ resolution structure
(final R/Rfree 0.183/0.199; see Table S1)
showed unambiguously (Figures 5 and
6) that residues 15–38 of VAMP8 form
a single a helix with residues between
Phe16 and Arg37 contacting CALMANTH,
consistent with the truncation data (Fig-
ure 3). The VAMP8 helix fitted into the
spatially complementary groove of
CALMANTH, lined by residues from helix
9 and helix 10, which was blocked by
helix 11 in the unliganded CALMANTH
structures and by dimerization in
CALMANTH(1-264). There was a small
movement of helices 9 and 10 with
respect to each other that caused a slightwidening of the groove as comparedwith the unliganded domain
structure (Figure S5). No electron density was visible for 17
residues that connect the last ordered residue of CALM with
the first of VAMP8. This would allow considerable flexibility in
the positioning of the VAMP8 and indeed in the crystals where
it bound to CALMANTH a VAMP8 SNARE motif could reach an
adjacent ANTH domain to which it was not covalently linked.
Key residues in the interaction, 13 on VAMP8 and 16 on
CALM, are spread throughout the interface between the two
proteins (Figure 5). This shows that the binding is not a short,
linear motif-mediated interaction that is typical of standard
adaptor/cargo interactions. Eleven of the thirteen key interact-
ing residues are conserved between VAMPs 8, 3, and 2 (Fig-
ure 3A), suggesting that they bind CALMANTH in a similar
manner. The residues in the CALMANTH:VAMP8 interface are
highly conserved from human to fish. The interface is mainly
hydrophobic in nature, burying a total of 1500A˚2 of accessible
surface area (Krissinel and Henrick, 2007), and a full list of inter-
acting residues is given in Figure 5D. The residues Lys24 and
Met27 of VAMP8 play key roles in the interaction, explaining
their initial identification as residues of importance for VAMP
endocytosis (Grote et al., 1995) (Lewis et al., 2000). Mutation
of these residues to alanines in VAMP8 abolished the interac-
tion with CALMANTH in vitro as shown by GST pull downs and
quantified by ITC (Figures 6D and 6E), as did mutations of
the analogous residues in VAMP2 and VAMP3 (data not
shown). The single Met27Ala mutation when introduced into
VAMP8 abolished the VAMP8:CALM interaction, whereas the
Lys24Ala mutation on its own only weakened the interaction.
The latter is to be expected since in VAMP2 and VAMP3, which
also bind directly to CALMANTH albeit more weakly, the equiva-
lent residues are valines. When transferred to the in vivo situa-
tion, the non-CALM binding Lys24AlaMet27Ala mutant of
VAMP8 accumulated on the cell surface and failed to be inter-
nalized (Figures 6H and 6I).
GST pull-down experiments demonstrated that mutation of
hydrophobic residues in CALMANTH that participate in VAMP8
binding, Leu219Ser, Phe240Ala, Met244Lys, Ile247Asp, and
Leu251Ser, all abolished the interaction between the two
proteins in vitro (Figures 6B and 6C) without affecting the fold
(as judged by expression levels and circular dichroism, data
not shown). Two of these, Leu219Ser and Met244Lys, whose
lack of binding was confirmed by ITC (Figures 6B and 6C),
were introduced into myc-tagged, siRNA-resistant CALM.
When transfected into cells expressing VAMP8HA, depletion of
endogenous CALM by siRNA caused the SNARE to be retained
at the plasmamembrane, because it could no longer be internal-
ized (Figures 6F and 6G). This is in contrast to cells transfected
with wild-type myc-tagged siRNA-resistant CALM, which
retained the ability to internalize VAMP8HA upon endogenous
CALM depletion (Figures 6F and 6G, 1B, and S1C). When taken
together, the data presented in this study demonstrate that
VAMP8 and the similar small R-SNAREs VAMP3 and VAMP2
are internalized from the plasma membrane by clathrin-
mediated endocytosis due to a direct interaction with the clathrin
adaptor CALM.
SNARE Complex Formation and Binding by CALM
Are Mutually Exclusive Processes for VAMP8
Superposing the structure of the N-terminal half of the VAMP8
SNARE motif with the same portion of VAMP8 from the SNARE
complex formed from VAMP8, Syntaxin7, Syntaxin8, and Vti1b
(Antonin et al., 2002) demonstrates that, not only does VAMP8Cadopt the same gently curving conformation in both complexes,
but when the complex structures are overlayed via the VAMP8
molecules they contain, helices 9 and 10 of CALMANTH superim-
pose on the SNARE motifs of Syntaxin8 and Syntaxin7, respec-
tively (Figure 7A). Comparison of the two complex structures
thus demonstrates that CALM binding and SNARE complex
formation by VAMP8 must be mutually exclusive processes.
This is confirmed by recombinant protein binding experiments,
which show that GST-VAMP8 binds CALMANTH, but GST-
VAMP8 complexed with SNAP23 and syntaxin3 (residues
195–253) does not (Figure 7B). It is important to note that the
Lys24AlaMet27Ala, non-CALMbindingmutant of VAMP8 cannot
be internalized but, as we show in this work, is able to form
SNARE complexes with its cognate plasma membrane SNARE
partners. These observations show that, contrary to a previous
proposal (Gordon et al., 2009), the ability of short R-SNAREs to
form SNARE complexes and the ability to be endocytosed
must in fact be independent of each other.
CALMANTH Binds VAMP8 and PtdIns4,5P2
Simultaneously
Since the binding sites on CALMANTH for PtdIns4,5P2 and
a VAMP are on opposite ends of the ANTH domain, it is probable
that both sites could bind simultaneously to their ligands. If this
were indeed the case, avidity effects would result in greatly
increased binding of CALM to a membrane containing both
ligands when compared to the binding to membranes containing
only one of the ligands, i.e., the KD of the apparent binding to
liposomes containing both ligands would be much lower than
the average value of the individual KDs for the two ligands
measured separately. To investigate whether or not simulta-
neous PtdIns4,5P2 and VAMP binding does indeed occur, the
binding of CALM to liposomes containing PC/PE/PtdIns4,5P2,
PC/PE+VAMP8 andPC/PE/PtdIns4,5P2+VAMP8was compared
using liposome-based SPR. Figure 7C shows that indeed there is
an almost order of magnitude decrease in KD (i.e., increase in
apparent affinity) over the average of the KDs for the individual
ligands when both ligands are present in the same liposome
membrane. Thus CALM must be able to bind simultaneously to
PtdIns4,5P2 and VAMP8.
Conformation of Membrane-Embedded VAMPs
when Bound to CALM
Given that CALMANTH can bind PtdIns4,5P2 and a small
R-SNARE VAMP simultaneously and based on the structural
identification of the binding sites for a VAMP and PtdIns4,5P2,
the following deductions can be made. To allow simultaneous
binding to a membrane-embedded VAMP and PtdIns4,5P2 to
occur, the amino-terminal half of the VAMP SNARE motif must
be able to reach its binding site, which is at a distance of around
50A˚ from the membrane surface. Thus, the 38 residues between
the end of the CALM binding sequence and the start of the trans-
membrane helix of a VAMP8 molecule must be able to stretch at
least this far. The published NMR and CD studies and our own
CD measurements (data not shown) indicate that in fact the
entire cytoplasmic domain of short VAMPs has no secondary
structure in solution (Fasshauer et al., 1997; Fiebig et al., 1999;
Hazzard et al., 1999). In such an unstructured conformation,ell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc. 1123
Figure 4. Structure of the CALMANTH Domain
(A) Ribbon representation of the structure of the CALMANTH domain colored from pink (residue 19) to purple (residue 288). Helices are numbered as in (Ford et al.,
2001) with no a6. The insets show 2FO–FC electron density contoured at 1.2 s for the well- and poorly-ordered a11 helix in the two CALMANTH molecules in the
asymmetric unit (designated chains A and B).
(B) Surface representation of helices a1-a10 of the CALMANTH domain colored from high (dark green) to low (white) hydrophobicity oriented as in (A). The
hydrophobic groove in which helix a11 and the ten preceeding residues sit can be clearly seen.
(C) GST pull-down expriments using GST, GSTVAMP8, and the His6MycCALMANTH proteins indicated. Top panel: Coomassie blue stained gel. Lower panel:
western blot probed with anti-myc. Residues 1–289 but not 1–264 of CALMANTH bound to GSTVAMP8.
(D) ITC quantitating the binding of residues 1–264 of CALMANTH to VAMP8. CALMANTH(1-264) (black triangles) showed no measurable binding to VAMP8 whereas
WT CALMANTH(1-289) bound with a KD of 20 ± 1mM (black squares). Data for CALMANTH(1-264) is offset by 0.2 mcal/sec for clarity.
(E) Structure of the CALMANTH(19-264) dimer. One monomer is colored pink/purple and the other blue. The view is rotated by 60
 around the vertical axis
relative to (A).
1124 Cell 147, 1118–1131, November 23, 2011 ª2011 Elsevier Inc.
Figure 5. Structure of the CALMANTH(1-264):VAMP8(11-41) Chimera
(A) Overall structure of the complex with CALMANTH colored as in Figure 4 with VAMP8 colored from pale (residue 15) to dark (residue 37) green. The relative
position of the membrane (gray bar) is inferred from the position of the PtdIns4,5P2 (marked as PIP2) binding site on CALMANTH as in 1HF8. The dotted line is
a schematic representation of how the remainder of the cytoplasmic portion of VAMP8 domain connects its CALM binding helix to its transmembrane helix.
(B) Orthogonal views of the CALMANTH:VAMP8 complex shown in molecular surface representation colored as in (A).
(C) Spatial complementarity of the CALMANTH:VAMP8 interface with key side chains involved in the binding of CALMANTH by VAMP8 shown. Molecular details of
the interactions of the key residues (i) K24 and (ii) M27 are shown.
(D) Schematic representation of VAMP8 residues 15–38. CALMANTH residues that make hydrophobic interactions with VAMP8 are labeled in black, those that
make salt bridge interactions with VAMP8 are labeled in blue and those that make hydrogen bonds with VAMP8 are labeled in turquoise.
(E) The final refined VAMP8 helix (green sticks) is shown in unbiased (FO–FC) electron density contoured at 3.5 s calculated before the addition of the helix to the
model (left panel). The VAMP8 helix lies on the same face as, but differs significantly from, the orientation of helix a11 (purple sticks) in the unliganded CALMANTH
structure (right panel).
See also Figure S5.the relevant portion of the VAMP’s cytoplasmic domain could
stretch up to 130A˚. This is easily sufficient to allow a single
CALM molecule, to simultaneously bind a VAMP8 molecule
and a PtdIns4,5P2 molecule from the same membrane.
In support of this model in which most or all of the portion of
small R-SNARE VAMPs between their CALM binding helices
and their transmembrane helices is unstructured, insertion of
helix-disrupting proline residues in the predicted unstructured(F) Surface representation of the CALMANTH(1-264) dimer with onemonomer colored
(A). Formation of the dimer obscures the surface buried by helix a11 in CALMAN
(G) Sequence of CALMANTH(1-289). Secondary structure is shown above the se
et al., 2001).
See also Figure S4.
CC-terminal half of the SNARE motif at positions Leu44 and
Leu51 of VAMP8 does not inhibit its ability to bind CALM or to
be endocytosed (Figures 7D–7F and S6). It does, however,
prevent SNARE complex formation with SNAP23 and Syntaxin3
(Figure 7B), which relies on the VAMP being able to form a helix
over the entire length of its SNAREmotif. In contrast, introducing
proline residues at positions Leu16 and Val23 in the CALM
binding helix of VAMP8 blocks the interaction between the twoby hydrophobicity as in (B) and the other monomer colored blue, oriented as in
TH(1-289) which is proposed to be the VAMP8 binding site.
quence representing helices a1 to a11; a6 has been omitted as per (Ford
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Figure 6. Mutation of Key Residues in the CALMANTH:VAMP8 Interface Abolishes Their Interaction In Vitro and the Endocytosis of VAMP8
In Vivo
(A) Structure of theCALMANTH:VAMP8 complex ‘‘opened out like a book’’ as indicated by the arrows. Residues whosemutation affect binding betweenCALMand
VAMP8 are colored and labeled in red, while mutations that have no effect are colored and labeled in gray.
(B) Pull-down experiments using GSTVAMP8 and WT or mutant His6MycCALMANTH as indicated. Top panel: Coomassie blue stained gel. Lower panel: western
blot probed with anti-myc. The mutations L219S, F240A, M244K, I247D, and L251S in His6MycCALMANTH abolished binding to VAMP8.
(C) ITC quantitating the binding of certain point mutant versions of CALMANTH to VAMP8. The wild-type CALMANTH binds with a KD17 ± 1mM (black squares)
whereas CALMANTH L219S (black circles) andM244K (open triangles) showed nomeasurable interaction with VAMP8. Data for CALMANTH L219S andM244K are
translated by 0.3 mcal/s and 0.7 mcal/s respectively.
(D) GST pull-down experiments using His6MycCALMANTH and WT or mutant GSTVAMP8 fusion proteins as indicated. Top panel: Coomassie blue stained gel.
Lower panel: western blot probed with anti-myc. Wt GSTVAMP8 bound CALMANTH whereas the K24AM27A VAMP8 did not. The GSTVAMP8 K24A mutant
interacted weakly with CALMANTH, however, the single M27A mutation of VAMP8 was sufficient to completely abolish the interaction with CALMANTH.
(E) ITC quantitating the binding of K24AM27A mutant version of VAMP8 to CALMANTH. Wt GSTVAMP8 bound wt CALMANTH with a KD17 ± 1mM (black squares)
whereas GSTVAMP8 K24AM27A (black circles) showed no measurable interaction. Data for GSTVAMP8 K24AM27A is translated by 0.3 mcal/s for clarity.
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proteins and prevents VAMP8 endocytosis as well as SNARE
complex formation. These observations also are in line with the
assertion made earlier that SNARE complex formation and the
ability to be endocytosed are not linked, which disagrees with
the interpretation of data in (Gordon et al., 2009).
DISCUSSION
The endocytic vesicles in most cells must incorporate the
R-SNAREs that will allow them to fuse with their target endo-
some (likely VAMP8 and VAMP3 [Antonin et al., 2000; McMahon
et al., 1993]). Alternatively, if they are to undergo immediate recy-
cling without passing through an endosomal compartment, as
has been proposed for neuronal synaptic vesicles, the vesicles
need to be able to fuse with the plasma membrane, for which it
is believed they use VAMP2 (Grote et al., 1995). Vesicles
destined for endosomes must also return any SNAREs that
have previously been used for fusion with the plasma membrane
for reuse in subsequent vesicle/organelle fusion events. Such
SNAREs include VAMP3 and VAMP8 for recycling back to the
plasma membrane; VAMP7 and VAMP8 for endosome/lyso-
some biogenesis (Advani et al., 1998; Antonin et al., 2000; Pryor
et al., 2004); VAMP8, VAMP7 and VAMP2 for the regulated
secretion of lysosomes with the plasma membrane (reviewed
in Chaineau et al., 2009); and VAMP4 for TGN-to-endosome
transport (Steegmaier et al., 1999; Tran et al., 2007). VAMP7,
which is active on late endocytic organelles (Advani et al.,
1998; Pryor et al., 2004), has been shown to be endocytosed
in an inactive cis-SNARE complex with a SNAP and a syntaxin
family member (Pryor et al., 2008) through binding to the clathrin
adaptor and ArfGAP Hrb. Transport in an inactive form prevents
erroneous VAMP7-mediated fusion of endocytic vesicles with
degradative late endosomes and lysosomes.
In contrast, we demonstrate that VAMP8, VAMP3, and
VAMP2, which are required for the fusion of endocytic vesicles
with their target early endosomes, are endocytosed in an
uncomplexed and therefore essentially active form through their
interaction with CALMANTH. However, since binding to CALM
and participation in SNARE complexes are mutually exclusive
processes, as both binding events utilize the same face of the
VAMP, it would be more correct to state that VAMPs 8, 3, and
2 are endocytosed in only a potentially active form, as their
conserved SNARE motifs are shielded by being bound to
CALMANTH. Corecognition of PtdIns4,5P2 markedly increases
the strength of binding betweenCALMand amembrane contain-
ing both a small R-SNARE VAMP and PtdIns4,5P2. In order for(F) Cells expressing either VAMP8-HA alone, or VAMP8-HA plus Myc-tagged s
and endogenous CALM was depleted by siRNA treatment. The cells were then
permeabilized and labeled with anti-CALM. The scale bar represents 20 mm.
(G) Endocytosis of anti-HA in cells coexpressing VAMP8-HA and siRNA-resistant
the cells at 4C, then the cells were warmed to 37C for 2–30 min and antibody
derived from at least 3 separate experiments; the error bars show the SEM. Expres
of the two CALM mutants does not.
(H) Localization of anti-HA in cells expressing wild-type or K24AM27A mutant VA
processed for immunofluorescence. Unlike the cells expressing wild-type VAMP
membrane. The scale bar represents 20 mm.
(I) Endocytosis of anti-HA in cells expressing wild-type or K24AM27A mutant V
negligible endocytosis of the mutant construct.
Ca small R-SNARE VAMP to bind to CALMANTH, helix 11 of the
ANTH domain must be displaced. This dissociation will be facil-
itated by the fact that helix11 is only poorly associated with the
rest of the ANTH domain (helices 1–10) (Figure 4) and may be
further modulated by the C-terminal tail of CALM that follows
helix11 binding to the clathrin terminal domains that are dis-
played on the underside of the polymeric clathrin lattice (Morgan
et al., 2000). It should be noted that despite it being necessary to
truncate CALMANTH at residue 264 in order to obtain the struc-
ture of the CALMANTH:VAMP8 complex, the displacement of
helix11 must have occurred in our biochemical assays as all
were performed on residues 1–289 of CALMANTH.
Following scission of an endocytic clathrin-coated vesicle
(CCV), the vesicle will uncoat by processes that include
PtdIns4,5P2 hydrolysis and clathrin cage disassembly. Once
PtdIns4,5P2 is hydrolyzed, the avidity effect generatedby a single
CALMmolecule simultaneously binding PtdIns4,5P2 and a small
R-SNARE VAMP will vanish leaving only the weak, transient
R-SNARE:CALM interaction. The two proteins will therefore
quickly dissociate. In order tominimise the energetically unfavor-
able situation of the hydrophobic face of an amphipathic helix
being exposed to the aqueous environment, the N-terminal half
of the SNARE motif of the short R-SNAREs, while still remaining
as a helix, switches to lying on the surface of the vesicle
membrane (Ellena et al., 2009). In the case of other SNAREs
such as the syntaxins and longin domain SNAREs, the SNARE
motifs can be shielded from the aqueous environment by binding
back on their N-terminal regulatory domains, which are not
present in the small R-SNAREs. On reaching its final destination,
the VAMP will now form tight, energetically favorable complexes
with its cognate Q-SNAREs on an endosome and so drive fusion
between the endocytic vesicle and endosomal membranes.
Thus in the cell, the SNARE motif of a small R-SNARE is never
free but interacts with either CALM, a membrane surface or is
part of a cognate SNARE complex (Figure 7G).
Nonsense point mutations in CALM are responsible for hema-
topoietic and iron metabolism abnormalities, growth retardation,
and shortened life span in fit1mice (Klebig et al., 2003), the stron-
gest phenotypes resulting from premature translational termina-
tion in the CALMANTH domain. The CALM/PICALM gene has also
been directly implicated in alterations in cognitive function with
increasing age (Mengel-From et al., 2011) in risk of developing
Alzheimer’s disease (Harold et al., 2009) and in modifying the
toxicity of Ab in a yeast, C. elegans and primary rat cortical
neuron models (Treusch et al., 2011). These pathophysiological
effects could, until now, only be explained by the role of CALMiRNA-resistant CALM (CALMres: wt, L219S, or M244K) were mixed together
fixed without permeabilization and labeled with anti-HA antibody, and then
wild-type, L219S or M244Kmutant myc-tagged CALM. Antibody was bound to
remaining at the cell surface was quantified by flow cytometry. Each point is
sion of the CALMconstruct rescues the knockdown phenotype, but expression
MP8-HA. The cells were allowed to endocytose the antibody for 40 min, then
8, the cells expressing the mutant have retained the antibody on the plasma
AMP8-HA, using the flow cytometry assay described in Figure S1B. There is
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Figure 7. Binding of CALMANTH and SNARE Complex Formation by VAMP8 Are Mutually Exclusive
(A) Comparison of the mode of VAMP8 binding to CALMANTH and to Syntaxin7:Syntaxin8:Vti1b (PDB 1GL2) (Antonin et al., 2002) made by superimposing the
VAMP8 residues 15–39 from the two complexes. VAMP8 adopts the same superhelical twist in both structures and helices a9 and a10 of CALMANTH correspond
to the helices of Syntaxin 8 and Syntaxin 7, respectively.
(B) Formation of GSTVAMP8:SNAP23:Synatxin3(195–253) SNARE complexes (see Supplemental Information) and their binding to CALMANTH. Pull-down
experiments using His6MycCALMANTH and theGST fusion proteins indicated. Top panel: Coomassie blue stained gel. Lower panel: western blot probedwith anti-
myc. SNARE complexes formed with GSTVAMP8 wt and K24AM27A but not with GSTVAMP8 L16PV23P or L44PL51P. Neither the wt VAMP8 SNARE complex
nor the K24AM27A SNARE complex bound CALMANTH indicating that SNARE complex formation and CALMANTH binding shown are mutually exclusive events.
(C) Avidity of CALM binding to PtdIns4,5P2 and VAMP8. Shown are the sensorgrams for the concentration dependent binding of CALM to membranes with
captured VAMP8 (top: calculated KD0.9 ± 0.15 mM), membranes with PtdIns4,5P2 (middle: calculated KD1.9 ± 0.45 mM) and membranes with both, PtdIns4,5P2
and captured VAMP8 (bottom: calculated KD0.17 ± 0.03 mM). Given are the mean values and SD of four independent measurements The affinity of CALM
increases by 8.5 fold over the average KD for the two ligands when VAMP8 and PtdIns4,5P2 are bound simultaneously.
(D) Pull-down experiments using His6MycCALMANTH and wt and mutant GSTVAMP8 fusion proteins as indicated. Top panel: Coomassie blue stained gel. Lower
panel: western blot probed with anti-myc. The GSTVAMP8mutants L16PV23P and K24AM27A (see also Figure 6) do not bind CALMANTH. However, GSTVAMP8
L44PL51P bound CALMANTH with a similar strength to wt GSTVAMP8.
(E) ITC quantitating the binding of point mutated versions of VAMP8 to CALMANTH. The binding of wt CALMANTH and GSTVAMP8 L44PL51P (open circles) was
comparable to that of wt CALMANTH and wt GSTVAMP8 (black squares) (KDs of 23 ± 2mM and 17 ± 1mM respectively). However, GSTVAMP8 L16PV23P (open
triangles) and GSTVAMP8 K24AM27A (black circles) both showed no measurable interaction with CALMANTH. Data for GSTVAMP8 L16PL23P, L44PL51P and
K24AM27A are translated by 0.3 mcal/s, 1.5 mcal/s and 1.9 mcal/s respectively for clarity.
(F) Localization of anti-HA in cells expressing different VAMP8-HA constructs. The cells were allowed to endocytose the antibody for 40 min, then processed for
immunofluorescence. The cells expressing wt VAMP8 and the L44PL51P mutant have endocytosed the antibody, but the cells expressing the L16PV23P mutant
have mainly retained the antibody on the plasma membrane similar to the K24AM27A mutant. The scale bar represents 20 mm.
(G) Schematic representation of the model of VAMP8 trafficking from the plasma membrane. The clathrin adaptor CALM binds simultaneously to the R-SNARE
VAMP8 and PtdIns4,5P2 (labeled PIP2) at the plasmamembrane. CALM is released from the surface of an endocytosed vesicle when PtdIns4,5P2 hydrolyzed and
the clathrin cage disassembled and the hydrophobic CALM-binding helix of VAMP8 now ‘‘lies’’ on the vesicle’s surface (Ellena et al., 2009). Finally VAMP8 forms
a trans-SNARE complex with its cognate SNAREs on an early endosome to drive vesicule fusion. Thus throughout the interaction of the hydrophobic VAMP8
SNARE motif with the aqueous environment is minimized.
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in linking clathrin to the PtdIns4,5P2-containing membrane
during endocytosis, a role replicated by all clathrin adaptors.
The work presented here raises the possibility that such effects
are related to CALM’s ability to directly drive the endocytosis
of the small R-SNAREs VAMP8, VAMP3, and VAMP2, since
failure to correctly transport these small R-SNARE VAMPs to
early endosomes as a result of a reduction in CALM levels would
perturb subsequent trafficking of a wide variety of proteins
through the endocytic pathway. In the case of Alzheimer’s espe-
cially it appears that any alterations in vesicle trafficking give rise
to increased levels of Ab production, presumably by modifying
the localization of Amyloid Precursor Protein (APP) or that of its
processing proteases (a-, b-, and g secretases) (Burgos et al.,
2010; Lee et al., 2008; Sannerud and Annaert, 2009). Further, it
has been documented that a major pathway for clearance of
Aß from the brain parenchyma is endocytosis by various cell
types including astrocytes, microglia, and endothelial cells.
The latter may further mediate Aß clearance from the brain
through the blood-brain-barrier by transcytosis, and it is of
note that these cells were shown to possess the highest levels
of CALM expression in the brain (Baig et al., 2010; Bu, 2009).
This provides another possible explanation for why CALM has
been linked to risk of Alzheimer’s disease since CALM should
play a key role in this endocytic process by selecting the
R-SNAREs needed both for endocytic vesicle/endosome fusion
and for subsequent fusion events along the endocytic pathway.
In summary, we have provided insight into the molecular
mechanism by which the post-Golgi small R-SNAREs bind
specifically to the ubiquitously and highly expressed endocytic
clathrin adaptor CALM, recently confirmed in Koo et al. (2011).
This ensures that the SNAREs required for fusion with the endo-
somal system and for subsequent trafficking steps are actively
selected into endocytic CCVs. This ability to mediate the
endocytosis of small R-SNARE VAMPs from the cell’s limiting
membrane provides a possible explanation for the association
of CALM with a variety of both neurological and other disorders.
EXPERIMENTAL PROCEDURES
For a list of the constructs and full materials and methods used in this study,
please see the Extended Experimental Procedures.
Cell Biology
HeLaM cells were used for all experiments. For most experiments, the cells
were stably transfected with HA-tagged wild-type or mutant VAMPs (2, 3,
and 8), and cell lines were selected that expressed the construct at low levels
so as not to saturate sorting machinery. For some experiments, the cells were
additionally transfected with myc-tagged, siRNA-resistant wild-type or mutant
CALM, and cell lines were selected that expressed the tagged CALM at similar
levels to endogenous CALM. The steady state localization of the constructs
and other proteins, both under control conditions and after siRNA-mediated
knockdowns, was observed by immunofluorescence microscopy. Endocy-
tosis kinetics were measured using either a flow cytometry-based antibody
uptake assay for the tagged VAMPs, or a radioiodinated ligand uptake assay
for other surface receptors. Details of transfection and knockdown conditions,
immunolabelling, and endocytosis assays are all described in Supplemental
Information.
Protein Expression and Purification
All recombinant proteins were expressed in BL21(DE3) pLysS E. coli for 16 hr
at 22C after induction with 0.2 mM IPTG at 37C and purified by standardCprocedures on glutathione sepharose and/or Ni2+-NTA agarose as appro-
priate. GST-tagged proteins were eluted with free glutathione or by thrombin
cleavage of the GST-tag while fusion proteins were bound to the beads.
His6-tagged proteins were eluted with buffer containing 300mM imidazole.
All proteins were subsequently purified by S200 gel filtration.
Recombinant Protein Pull Downs
SNARE:adaptor interactions were tested using varying concentrations of GST-
tagged SNAREs and relevant His6myc-tagged prey proteins. SNARE
complexes were made with a 3-fold excess of SNAP23 and syntaxin3 to
GSTVAMP8 and purified by GST sepharose and gel filtration. SNARE com-
plex:adaptor interactions were tested using 2 nmoles of 1:1:1 GST-tagged
complex incubated with His6myc-CALMANTH. All binding experiments were
carried out in 1 ml of buffer supplemented with 30 ml glutathione beads and
incubated with constant agitation at 4C. The supernatant removed and the
beads washed with 1 ml of buffer, three times. Bound proteins were analyzed
by SDS-PAGE and western blots probed with anti-myc antibody (9E10 Santa
Cruz Biotechnologies).
Isothermal Titration Calorimetry
Due to yield and solubility issues, GST-tagged SNAREs were used. A VPITC
machine (GE Healthcare) was used to titrate 37 injections of 4–8 ml 2 mM
His6MycCALMANTH or GST cleaved Epsin1ENTH proteins into 0.15 mM SNARE
proteins. Titration curves were fitted using ORIGIN software. Figures show
a representative example of each experiment with the KD and associated
confidence of the fit (SEM) shown; n = 0.9-1.1. KDs quoted in the text are
the average of all runs.
Surface Plasmon Resonance
Liposome-based SPR was carried out using a Biacore 3000 (GE Healthcare)
with GST cleaved CALMANTH and Epsin1ENTH adaptor proteins as analytes
and PC/PE liposomes supplemented with 5% PtdIns4,5P2 and/or His12-
tagged VAMP8 attached via 5% DGS-NTA(Ni). The binding was monitored
during one minute injections at 50 ml/min at concentrations ranging from
10 nM to 50 mM. The kinetic parameters were calculated after background
(PC/PE binding) subtraction.
Crystallization, Data Collection, Structure Solution, and Refinement
Crystals ofCALMANTH (1-289),CALMANTH(1-264), andCALMANTH(1-264): VAMP8(11-41)
weregrown insittingdropsat16CusingGST fusionproteins formwhich theGST
had been cleaved. CALMANTH(1-289) was equilibrated against reservoirs contain-
ing 100 mM Bis Tris propane, 200 mM sodium malonate, 20% (w/v) PEG 3350;
CALMANTH(1-264) was equilibrated against reservoirs containing 15% v/v ethanol,
100mM imidazole (pH 8.0), 200mMMgCl2; CALMANTH:VAMP8was equilibrated
against reservoirs containing 100mMphosphate-citrate (pH 4.2), 200mMNaCl,
50% (v/v) PEG200. All structures were solved by molecular replacement using
previouslypublishedANTHdomain ofCALMasa startingmodel (1HF8).Detailed
descriptions of structure determination, refinement, and structural analysis can
be found in Supplemental Information. Structure factors and final refined coordi-
nates have been deposited in the PDBwith accession codes 3ZYK (CALMANTH),
3ZYL (CALMANTH(1-264)), and 3ZYM (CALMANTH(1-264):VAMP8(11-41)).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, one
table, and six figures and can be found with this article online at doi:10.
1016/j.cell.2011.10.038.
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